1. Home
  2. INSM vs DVN Comparison

INSM vs DVN Comparison

Compare INSM & DVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • DVN
  • Stock Information
  • Founded
  • INSM 1988
  • DVN 1971
  • Country
  • INSM United States
  • DVN United States
  • Employees
  • INSM N/A
  • DVN N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • DVN Oil & Gas Production
  • Sector
  • INSM Health Care
  • DVN Energy
  • Exchange
  • INSM Nasdaq
  • DVN Nasdaq
  • Market Cap
  • INSM 26.0B
  • DVN 21.5B
  • IPO Year
  • INSM 2000
  • DVN N/A
  • Fundamental
  • Price
  • INSM $145.10
  • DVN $34.78
  • Analyst Decision
  • INSM Strong Buy
  • DVN Buy
  • Analyst Count
  • INSM 19
  • DVN 21
  • Target Price
  • INSM $142.38
  • DVN $44.32
  • AVG Volume (30 Days)
  • INSM 3.0M
  • DVN 6.6M
  • Earning Date
  • INSM 10-30-2025
  • DVN 11-04-2025
  • Dividend Yield
  • INSM N/A
  • DVN 2.76%
  • EPS Growth
  • INSM N/A
  • DVN N/A
  • EPS
  • INSM N/A
  • DVN 4.44
  • Revenue
  • INSM $398,105,000.00
  • DVN $16,105,000,000.00
  • Revenue This Year
  • INSM $32.47
  • DVN $13.37
  • Revenue Next Year
  • INSM $126.03
  • DVN N/A
  • P/E Ratio
  • INSM N/A
  • DVN $7.83
  • Revenue Growth
  • INSM 21.15
  • DVN 7.79
  • 52 Week Low
  • INSM $60.40
  • DVN $25.89
  • 52 Week High
  • INSM $146.84
  • DVN $43.30
  • Technical
  • Relative Strength Index (RSI)
  • INSM 79.86
  • DVN 52.49
  • Support Level
  • INSM $128.02
  • DVN $33.31
  • Resistance Level
  • INSM $146.84
  • DVN $36.57
  • Average True Range (ATR)
  • INSM 3.66
  • DVN 0.86
  • MACD
  • INSM 0.71
  • DVN 0.02
  • Stochastic Oscillator
  • INSM 91.65
  • DVN 47.51

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About DVN Devon Energy Corporation

Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2024, Devon reported net proved reserves of 2.2 billion barrels of oil equivalent. Net production averaged roughly 848,000 barrels of oil equivalent per day in 2024 at a ratio of 73% oil and natural gas liquids and 27% natural gas.

Share on Social Networks: